Skip to main content
SpringerLink
Log in

Calcium Channel Blockers and the Risk of Cancer: A Preclinical Assessment

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

The preclinical evidence for a potential influence of calcium channel blockers (CCBs) on carcinogenesis is discussed in the light of a broad database from rodent carcinogenicity studies as well as literature data. In all bioassays performed in rats and mice on the dihydropyridine CCBs — nifedipine, nimodipine, nisoldipine, and nitrendipine — no evidence was found for a carcinogenic potential of these compounds. Calcium is an essential intracellular signal for cell proliferation and apoptosis. The crucial role of increased cell proliferation in all stages of carcinogenesis is well documented. Some indirect experimental evidence also points to a role of defective apoptosis in tumor promotion. CCBs uniformly inhibit cell proliferation, whereas the influence of CCBs on apoptosis is inconsistent, resulting in an inhibition or increase in apoptosis dependent on cell type. Accordingly, antitumorigenic effects of CCBs have been reported based on their antiproliferative action. A tumor-promoting effect of CCBs based on inhibition of apoptosis, however, remains purely speculative and, in fact, can be denied based on the results of in vivo bioassays. It is therefore concluded that there is no preclinical evidence that should give rise to concern over the carcinogenic potential of dihydropyridine-type CCBs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium-channel blockers increase the risk of cancer. Am J Hypertens 1996;9:695-699.

    Google Scholar 

  2. Williams GM, Iatropoulos J, Weisburger JH. Chemical carcinogen mechanisms of action and implication for testing methodology. Exp Toxic Pathol 1996;48:101-111.

    Google Scholar 

  3. Physicians' Desk Reference. Montvale, NJ: Medical Economics Data Production Company. 1995.

  4. Peto R, Pike MC, Dayne et al. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: Long-Term and Short-Term Screening Assays for Carcinogens: A Critical Appraisal. IARC Monographs, Suppl. 2, Lyon, France: IARC, 1980:311-426.

    Google Scholar 

  5. Ryan LM. Efficiency of age-adjusted tests in animal carcinogenicity experiments. Biometrics 1985;41:525-531.

    Google Scholar 

  6. Report of the NTP Ad Hoc Panel on Chemical Carcinogenesis Testing and Evaluation. U.S. Department of Health and Human Services, Research Triangle 1984:212.

  7. Lee P. Assumption in analyses of the bioassay: A statisticians view. In: Grice HC, Ciminera JL, eds. Carcinogenicity-The Design, Analysis, and Interpretation of Long-Term Animal Studies. New York: Springer, 1988:7.

    Google Scholar 

  8. Gart J, Krewski D, Lee P, Tarone R, Wahrendorf J. Statistical Methods in Cancer Research, Vol. III: The Design and Analysis of Long-Term Animal Experiments. Lyon, France: IARC, 1987.

    Google Scholar 

  9. Nyska A, Waner T, Galliano A, Fick A. Constipation and mega-colon in rats related to treatment with Oxodipine, a calcium antagonist. Toxicol Pathol 1994;22:589-594.

    Google Scholar 

  10. Bomhard E, Karbe E, LÖ;ser E. Spontaneous tumors of 2000 Wistar TNO/W70 rats in 2-year carcinogenicity studies. J Environ Pathol 1986;7:35-52.

    Google Scholar 

  11. Bomhard E, Rinke M. Frequency of spontaneous tumors in Wistar rats in 2-year studies. Exp Toxicol Pathol 1994;46: 17-29.

    Google Scholar 

  12. Bomhard E. Frequency of spontaneous tumors in NMRI mice in 21-month studies. Exp Toxicol Pathol 1993;45: 269-289.

    Google Scholar 

  13. Alison RH, Capen CC, Prentice DE. Neoplastic lesions of questionable significance to humans. Toxicol Pathol 1994;22: 179-186.

    Google Scholar 

  14. Purchase J. Current knowledge of mechanisms of carcinogenicity: Genotoxins vs. non-genotoxins. In: McAuslane JAN, Limley CE, Walker SR, eds. The Carcinogenicity Debate. Quay Publishing, Lancaster, UK 1992:3-24.

    Google Scholar 

  15. Grasso P, Hinton RH. Evidence for and possible mechanisms of non-genotoxic carcinogenesis in rodent liver. Mutat Res 1991;248:271-290.

    Google Scholar 

  16. Hoel DG, Haseman JK, Hogan MD, Huff J, McConnell EE. The impact of toxicity studies: Implications for risk assessment. Carcinogenesis 1988;9:2045-2052.

    Google Scholar 

  17. Monro A. Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? Exp Toxicol Pathol 1996; 48:155-166.

    Google Scholar 

  18. Ames BN, Gold LS. Too many rodent carcinogens. Science 1990;249:970-971.

    Google Scholar 

  19. Thorgeirsson UP, Dalgard DW, Reeves J, Adamson RH. Tumor incidence in a chemical carcinogenesis study of nonhuman primates. Regul Toxicol Pharmacol 1994;19:130-151.

    Google Scholar 

  20. Berridge MJ. The biology and medicine of calcium signalling. Mol Cell Endocrinol 1994;98:119-124.

    Google Scholar 

  21. Berridge MJ. Calcium signalling and cell proliferation. Bio Essays 1995;17:491-500.

    Google Scholar 

  22. Takuwa N, Zhou W, Takuwa Y. Calcium, calmodulin and cell cycle progression. Cell Signalling 1995;7:93-104.

    Google Scholar 

  23. Lu KP, Means AR. Regulation of the cell cycle by calcium and calmodulin. Endocr Rev 1993;14:40-58.

    Google Scholar 

  24. Whitfield J F. Calcium signals and cancer. Crit Rev Oncogen 1992;3:55-90.

    Google Scholar 

  25. Veigl ML, Vanaman TC, Sedwick WD. Calcium and calmodulin in cell growth and transformation. Biochem Biophys Acta 1984;738:21-48.

    Google Scholar 

  26. Dragan YP, Hully J, Crow R, Mass M, Pitot HC. Incorporation of bromodeoxyuridine in glutathione S-transferase-positive hepatocytes during rat multistage hepatocarcinogenesis. Carcinogenesis 1994;15:1939-1947.

    Google Scholar 

  27. Huang SN, Chisari FV. Strong sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 1995;21:620-626.

    Google Scholar 

  28. Robinson BG. Molecular genetics of thyroid and parathyroid neoplasia. Austr N Z J Surg 1995;65:77-79.

    Google Scholar 

  29. DiGiovanni J, Rho O, Xian W, Beltran L. Role of the epidermal growth factor receptor and transforming growth factor alpha in mouse skin carcinogenesis. Prog Clin Biol Res 1994;387:113-138.

    Google Scholar 

  30. DeKoster E, Buset M, Fernandes E, Deltenre M. Helicobacter pylori: The link with gastric cancer. Eur J Cancer Prev 1994;3:247-257.

    Google Scholar 

  31. Hulka BS, Liu ET, Lininger RA. Steroid hormones and risk of breast cancer. Cancer 1994;74:1111-1124.

    Google Scholar 

  32. Coffey RJ Jr., Meise KS, Matsui Y, Hogan BL, Dempsey PJ, Halter SA. Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7, 12-dimethylbenzanthracene. Cancer Res 1994;54:1678-1683.

    Google Scholar 

  33. Rosin MP, Saad el Din Zaki S, Ward AJ, Anwar WA. Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients. Mutat Res 1994;305:283-292.

    Google Scholar 

  34. Parkin DM, Ohshima H, Srivatanakul P, Vatanasapt V. Cholangiocarcinoma: Epidemiology mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev 1993;2:537-544.

    Google Scholar 

  35. Short BG. Cell proliferation and renal carcinogenesis. Environ Health Perspect 1993;101:115-120.

    Google Scholar 

  36. Croy RG. Role of chemically induced cell proliferation in carcinogenesis and its use in health risk assessment. Environ Health Perspect 1993;101:289-302.

    Google Scholar 

  37. Tomatis L. Cell proliferation and carcinogenesis: A brief history and current view based on an IARC workshop report. Environ Health Perspect 1993;101:149-151.

    Google Scholar 

  38. Fleckenstein A. Fundamental actions of calcium antagonists on myocardial cardiac pacemaker cell membranes. In Weiss GB, ed. New Perspectives on Calcium Antagonists. Clinical Physiology Series, American Physiological Society, 1981: 59-81.

  39. Kass GEN, Llopis J, Chow SC, Duddy SK, Orrenius S. Receptor-operated calcium influx in rat hepatocytes. J Biol Chem 1990;265:17486-17492.

    Google Scholar 

  40. Sperti G, Colucci WS. Calcium influx modulates DNA synthesis and proliferation in A7R5 vascular smooth muscle cells. Eur J Pharmacol 1991;206:279-284.

    Google Scholar 

  41. Handley DA, van Valen RG, Melden MK, Saunders RN. Supression of rat carotid lesion development by the calcium channel blocker PN 200-110. Am J Pathol 1986;124:88-93.

    Google Scholar 

  42. Hecker M, Winter I, Schray UB, Busse R. Inhibition of DNA synthesis in cultivated human endothelial cells by Ca-antagonists. Z Kardiol 1993;82:113.

    Google Scholar 

  43. Orth SR, Nobiling R, BÖ;nisch S, Ritz E. Inhibitory effect of calcium channel blockers on human mesangial cell growth: Evidence for actions independent of L-type Ca2+ channels. Kidney Int 1996;49:868-879.

    Google Scholar 

  44. Gelfand EW, Cheung RK, Grinstein S, Mills GB. Characterization of the role for calcium influx in mitogen-induced triggering of human T cells. Identification of calcium-dependent and calcium-independent signals. Eur J Immunol 1986;16:907-912.

    Google Scholar 

  45. Dugas B, Vazquer A, Klein B, Delfraissy JF, Rammou M, Gerard JP, Galanaud P. Early events in human B cell activation: Metabolic pathways vary according to the first signal used. Eur J Immunol 1986;16:1609-1614.

    Google Scholar 

  46. Brent LH, Butler JL, Woods WT Jr., Bubien JK. Transmembrane ion conductance in human B lymphocyte activation. J Immunol 1990;145:2381-2389.

    Google Scholar 

  47. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 1992; 52:2413-2418.

    Google Scholar 

  48. Worley JF, Strobl JS. Voltage-dependent calcium channels in MCF-7 human breast cancer cells and inhibition of cell growth by calcium channel antagonists. Cancer Chemother Pharmacol 1989;24:84.

    Google Scholar 

  49. Sugimoto K, Simard J, Haagensen DE, Labrie F. Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. Steroid Biochem. Mol Biol 1994;51: 167-174.

    Google Scholar 

  50. Bertrand V, Bastie MJ, Vaysse N, Pradayrol L. Inhibition of gastrin induced proliferation of AR4-2S cells by calcium channel antagonists. Int JCancer 1994;56:427-432.

    Google Scholar 

  51. .Codignola A, Tarroni P, Clementi F, Pollo A, Lovallo M, Carbone E, Sher E. Calcium channel subtypes controlling serotonin release from human small cell lung carcinoma cell lines. J Biol Chem 1993;268:26240-26247.

    Google Scholar 

  52. SchÜ;ller HM, Miller MS, Reznik GK. Antiproliferative effects of dihydropyridines on human lung cancer cell lines. Proc Am Assoc Cancer Res 1993;34:347.

    Google Scholar 

  53. Piontek M, Hengels KJ. Effect of calcium-modifying agents on the growth of human gastric carcinoma cells in vitro. Anticancer Res 1992;12:1559-1563.

    Google Scholar 

  54. Inokuchi N, Zeki K, Morimoto I, et al. Stimulatory effect of interleukin-1 alpha on proliferation through a Ca2+/calmodulin-dependent pathway of human thyroid carcinoma cell line, NIM 1. Jpn J Cancer Res 1995;86:670-677.

    Google Scholar 

  55. Kunert-Radek J, Stepien H, Stawowy A, Pawlikowski M. Involvement of calcium channels in control of the pituitary tumoral cell proliferation in vitro. Neuroendocrinol Lett 1989;11:339-345.

    Google Scholar 

  56. Lee YS, Sayeed MM, Wurster RD. Inhibition of cell growth and intracellular CA2 mobilization in human brain tumorcells by CA2 channel antagonists. Mol Chem Neuropathol 1994;22:81-95.

    Google Scholar 

  57. Schmidt WF, Huber KR, Ettinger RS, Neuberg RW. Antiproliferative effect of verapamil alone on brain tumor cells in vitro. Cancer Res 1988;48:3617-3621.

    Google Scholar 

  58. Jensen RL, Origitano TC, Lee YS, Weber M, Wurster RD. In vitro growth inhibition of growth factor stimulated meningioma cells by calcium channel antagonists. Neurosurgery 1995;36:365-374.

    Google Scholar 

  59. Bruserud O, Nesthus I, Pawelec G. In vitro effect of R-verapamil on acute myelogenous leukemia blast cells. Studies of cytokine secretion and cytokine-dependent blast proliferation. Cancer Chemother Pharmacol 1995;37:70-78.

    Google Scholar 

  60. Shirakawa F, Yamashita U, Oda S, Chiba S, Eto S. Calcium dependency in the growth of adult T-cell leukemia cells in vitro. Cancer Res 1986;46:658-661.

    Google Scholar 

  61. Okazaki T, Mochizuki T, Tashima M, Sawada H, Uchino H. Role of intracellular calcium ion in human promyelocytic leukemia HL-60 cell differentiation. Cancer Res 1986;46: 6059-6063.

    Google Scholar 

  62. Sato K, Ishizuka J, Cooper CW, et al. Inhibitory effect of calcium channel blockers on growth of pancreatic cancer cells. Pancreas 1994;9:193-202.

    Google Scholar 

  63. Hirai A, Ishizuka J, Cooper CW, Townsend CM, Thompson JC. Effect of calcium channel blockers on growth of colon cancer cells. Gastroenterology 1994;106:A392.

    Google Scholar 

  64. Corcoran GB, Fix L, Jones DP, et al. Apoptosis: Molecular control point in toxicity. Toxicol Appl Pharmacol 1994;128: 169-181.

    Google Scholar 

  65. Orrenius S, Apoptosis: Molecular mechanisms and implications for human disease. Intern Med 1995;237:529-536.

    Google Scholar 

  66. McConkey DJ, Orrenius S. Signal transduction pathways to apoptosis. Trends Cell Biol 1994;4:370-375.

    Google Scholar 

  67. Dowd DR. Calcium regulation of apoptosis. In: Means AR, ed. Advances in Second Messenger and Phosphoprotein Research, Vol. 30. New York: Raven Press, 1995:255-280.

    Google Scholar 

  68. Alnemri ES, Litwack G. Activation of internucleosomal DNA cleavage in human CEM lymphocytes by glucocorticoid and novobiocin. Biol Chem 1990;265:17323-17333.

    Google Scholar 

  69. Lam M, Dubyak G, Distelhorst CW. Effect of glucocorticosteroid treatment on intracellular calcium homeostasis in mouse lymphoma cells. Mol Endocrinol 1993;7:686-693.

    Google Scholar 

  70. Lennon SV, Kilfeather SA, Hallett MB, Campbell AK, Cotter TG. Elevations in cytosolic free Ca2+ are not required to trigger apoptosis in human leukemia cells. Clin Exp Immunol 1992;87:465-471.

    Google Scholar 

  71. Kluck RM, McDougall CA, Harmon BV, Halliday JW. Calcium chelators induce apoptosis-evidence that raised intracellular ionised calcium is not essential for apoptosis. BiochimBiophys Acta 1994;1223:247-254.

    Google Scholar 

  72. Zhu WH, Loh TT. Roles of calcium in the regulation of apoptosis in Hl-60 promyelocytic leukemia cells. Life Sci 1995;57:2091-2099.

    Google Scholar 

  73. Whyte MKB, Hardwick SJ, Meagher LC, Savill JS, Haslett C. Transient elevations of cytosolic free calcium retard subsequent apoptosis in neutrophils in vitro. Clin Invest 1993;92:446-455.

    Google Scholar 

  74. Rodriguez-Tarduchy G, Malde P, Lopez-Rivas A, Collins MKL. Inhibition of apoptosis by calcium ionophores in IL-3-dependent bone marrow cells is dependent upon production of IL-4+1. Immunology 1992;148:1416-1422.

    Google Scholar 

  75. Preston GA, Barrett JC, Biermann JA, Murphy E. Effects of alterations in calcium homeostasis on apoptosis during neoplastic progression. Cancer Res 1997;57:537-542.

    Google Scholar 

  76. Williams GT. Programmed Cell Death: Apoptosis and Oncogenesis. Cell 1991;65:1097-1098.

    Google Scholar 

  77. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993; 341:1251-1254.

    Google Scholar 

  78. Wright SC, Zhong J, Larrick JW. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 1994;8:654-660.

    Google Scholar 

  79. Bursch W, Oberhammer F, Schulte-Hermann R. Cell death by apoptosis and its protective role against disease. Trends Pharmacol Sci 1992;13:245-251.

    Google Scholar 

  80. Bursch W, Lauer B, Timmermann-Trosiener I, Barthel G, Schuppler J, Schulte-Hermann R. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promotors. Carcinogenesis 1984;5:453-458.

    Google Scholar 

  81. Schulte-Hermann R, Timmermann-Trosier I, Barthel G, Bursch W. DNA synthesis, apoptosis, and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res 1990;50: 5127-5135.

    Google Scholar 

  82. James NJ, Roberts RA. Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. Carcinogenesis 1996;17:1623-1632.

    Google Scholar 

  83. Martikainen P, Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 1990;17: 175-187.

    Google Scholar 

  84. Connor J, Sawczuk IS, Benson MC, Tomashefsky P, O'Toole KM, Olsson CA, Buttyan R. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988;13:119-130.

    Google Scholar 

  85. Juntti-Berggren L, Larson O, Rorsmann P, et al. Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes. Science 1993;261:86-90.

    Google Scholar 

  86. Leszczynski D, Zhao Y, Luokkamaeki M, Foegh ML. Apoptosis of vascular smooth muscle cells. Am J Pathol 1994; 145:1265-1270.

    Google Scholar 

  87. Shchepotin IB, Soldatenkov VA, Shabahang M, Buras RR, Nauta RJ, Evans SRT. The effect of hyperthermia and verapamil on primary and metastatic colon adenocarcinoma cell lines: Inhibition of proliferation, cell cycle distribution and onset of apoptosis. Oncol Rep 1995;2:879-884.

    Google Scholar 

  88. Shamash I, Davies DC;;, Lister TA. Apoptosis and cell proliferation control induced by pulsed calcium channel blockade in a low grade lymphoma cell line expressing BCL-2. Blood 1994;84:448A.

    Google Scholar 

  89. Balakumaran A, Campbell GA, Treinen Moslen M. Calcium channel blockers induce thymic apoptosis in vivo in rats. Toxicol Appl Pharmacol 1996;139:122-127.

    Google Scholar 

  90. Smith BM, Ginhart TD, Colburn NH. Extracellular calcium requirement for promotion of transformation in JB6 cells. Cancer Res 1986;46:701-706.

    Google Scholar 

  91. Tatsuta M, Iishi H, Baba M, Nakaizumi A, Uehara H, Taniguchi H. Effect of calcium channel blockers on gastric carcinogenesis and caerulein enhancement of gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Cancer Res 1990;50:2095-2098.

    Google Scholar 

  92. Nakaizumi A, Uehara H, Baba M, Iishi H, Tatsuta M. Inhibition by verapamil of cholecystokinin-enhancement of pancreatic carcinogenesis induced by azaserine in Wistar rats. Cancer Lett 1996;105:23-27.

    Google Scholar 

  93. Juraskova V, Sladek T. Antimetastatic action of diltiazem on LS/BL tumor cells in liver tumor-colony assay. Neoplasma 1990;37:343-348.

    Google Scholar 

  94. Onoda JM, Sloane BF, Taylor JD, Honn KV. Calcium channel blockers: Inhibition of tumor cell-platelet-endothelial cell interactions. Dev Oncol 1984;22:244-258.

    Google Scholar 

  95. Honn KV, Onoda JM, Taylor JD, Sloane BF. Antimetastatic therapy with calcium active compounds. In: Hellmann Eccles SA, ed. Treatment and Metastasis: Problems and Prospects. London. Taylor and Francis, 1984:259-262.

    Google Scholar 

  96. Timar J, Chopra H, Rong X, et al. Calcium channel blockers treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin αIIBβ3 and tumor-cell-induced platelet aggregation. Cancer Res Clin Oncol 1992;118:425-434.

    Google Scholar 

  97. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Clin Oncol 1991;9:17-24.

    Google Scholar 

  98. Gupta V, Kamath N, Tkalcevic GT, Singh SV. Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line. BiochemPharmacol 1994;47:1701-1704.

    Google Scholar 

  99. Cole K, Kohn E. Calcium-mediated signal transduction: Biology, biochemistry, and therapy. Cancer Metast Rev 1994; 13:31-44.

    Google Scholar 

  100. Zacharski LR, Moritz TE, Haakenson CM, Odonnell JF, Ballard HS. Chronic calcium antagonist use in carcinoma of the lung and colon, a retrospective cohort observational study. Cancer Invest 1990;8:451-458.

    Google Scholar 

  101. Brown M. Letter to the Editor. Lancet 1996;348:1166.

    Google Scholar 

  102. Jick H, Jick S, Derby LE, Vaslakis C, Myers MW, Meier CR. Calcium channel blockers and risk of cancer. Lancet 1997;349:525-528.

    Google Scholar 

  103. Olson JH, Sorensen HT, Friis S, etal. Cancer risk in users of calcium channel blockers. Hypertension 1997;29: 1091-1094.

    Google Scholar 

  104. Ad Hoc Subcommittee of the Liaison Committee of the WHO and the International Society of Hypertension. Effects of calcium antagonists on the risk of coronary heart disease, cancer and bleeding. J Hypertens 1997;15:105-115.

    Google Scholar 

  105. Anundi I. Calcium antagonists and cancer-what do studies of animals used in experiments show? Information from Lä;kemedelsverket 1997;8:1-4.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Toxicology, Bayer AG, Wuppertal, Germany

    Hans J. Ahr, Ernst Bomhard, Harald Enzmann, Eberhard Karbe, Harry Mager, Erich Sander & Gerhard Schlüter

Authors
  1. Hans J. Ahr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernst Bomhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harald Enzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eberhard Karbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Harry Mager
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Erich Sander
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gerhard Schlüter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahr, H.J., Bomhard, E., Enzmann, H. et al. Calcium Channel Blockers and the Risk of Cancer: A Preclinical Assessment. Cardiovasc Drugs Ther 12, 157–169 (1998). https://doi.org/10.1023/A:1007727010076

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007727010076

Search

Navigation